Back to All Trials
RecruitingPhase 3Infectious Disease

Vaccine Study for Respiratory Syncytial Virus (RSV)

$800
total
24 months
Duration
6
Total Visits
6500
Spots Remaining

About This Study

This vaccine trial aims to protect older adults from RSV, a common respiratory virus that can cause serious illness in seniors. The vaccine is administered as a single intramuscular injection.

Study Objectives

To evaluate vaccine efficacy in preventing RSV-associated lower respiratory tract disease over two RSV seasons.

Eligibility Requirements

Inclusion Criteria

  • Adults 60 years and older
  • Generally healthy or stable chronic conditions
  • No prior RSV vaccination
  • Able to attend all study visits
  • No immunocompromising conditions

Exclusion Criteria

  • Allergic reaction to any vaccine component
  • Fever or acute illness at enrollment
  • Receipt of other investigational vaccines
  • Immunosuppressive therapy

Frequently Asked Questions

Study Location

Emory University Hospital
Atlanta, GA 30322
Map View

Research Team

Dr. William Chang
Emory Vaccine Center
Vaccine Research Unit
rsv.vaccine@emory.edu(404) 555-0741

Study Timeline

Start DateJanuary 1, 2024
End DateJanuary 1, 2026
Enrollment18500 / 25000